Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab.

Velayos FS, Kahn JG, Sandborn WJ, Feagan BG.

Clin Gastroenterol Hepatol. 2013 Jun;11(6):654-66. doi: 10.1016/j.cgh.2012.12.035. Epub 2013 Jan 26.

PMID:
23357488
2.

Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis.

Kaplan GG, Hur C, Korzenik J, Sands BE.

Aliment Pharmacol Ther. 2007 Dec;26(11-12):1509-20. Epub 2007 Oct 11.

3.

Certolizumab pegol compared to natalizumab in patients with moderate to severe Crohn's disease: results of a decision analysis.

Ananthakrishnan AN, Hur C, Korzenik JR.

Dig Dis Sci. 2012 Feb;57(2):472-80. doi: 10.1007/s10620-011-1896-3. Epub 2011 Sep 11.

PMID:
21909990
4.

Can mucosal healing be a cost-effective endpoint for biologic therapy in Crohn's disease? A decision analysis.

Ananthakrishnan AN, Korzenik JR, Hur C.

Inflamm Bowel Dis. 2013 Jan;19(1):37-44. doi: 10.1002/ibd.22951.

PMID:
22416019
5.

Strategies for the prevention of postoperative recurrence in Crohn's disease: results of a decision analysis.

Ananthakrishnan AN, Hur C, Juillerat P, Korzenik JR.

Am J Gastroenterol. 2011 Nov;106(11):2009-17. doi: 10.1038/ajg.2011.237. Epub 2011 Jul 26.

PMID:
21788991
6.

Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease.

Yu AP, Johnson S, Wang ST, Atanasov P, Tang J, Wu E, Chao J, Mulani PM.

Pharmacoeconomics. 2009;27(7):609-21. doi: 10.2165/11312710-000000000-00000.

PMID:
19663531
7.

Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial.

Steenholdt C, Brynskov J, Thomsen OØ, Munck LK, Fallingborg J, Christensen LA, Pedersen G, Kjeldsen J, Jacobsen BA, Oxholm AS, Kjellberg J, Bendtzen K, Ainsworth MA.

Gut. 2014 Jun;63(6):919-27. doi: 10.1136/gutjnl-2013-305279. Epub 2013 Jul 22.

PMID:
23878167
8.

Cost-utility analysis of biologic treatments for moderate-to-severe Crohn's disease.

Tang DH, Armstrong EP, Lee JK.

Pharmacotherapy. 2012 Jun;32(6):515-26. doi: 10.1002/j.1875-9114.2011.01053.x. Epub 2012 Apr 23.

PMID:
22528603
9.

Risks and benefits of infliximab for the treatment of Crohn's disease.

Siegel CA, Hur C, Korzenik JR, Gazelle GS, Sands BE.

Clin Gastroenterol Hepatol. 2006 Aug;4(8):1017-24; quiz 976. Epub 2006 Jul 14.

PMID:
16843733
10.

Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease.

Marchetti M, Liberato NL, Di Sabatino A, Corazza GR.

Eur J Health Econ. 2013 Dec;14(6):853-61. doi: 10.1007/s10198-012-0430-7. Epub 2012 Sep 14.

PMID:
22975794
11.

Cost-utility of initial medical management for Crohn's disease perianal fistulae.

Arseneau KO, Cohn SM, Cominelli F, Connors AF Jr.

Gastroenterology. 2001 Jun;120(7):1640-56.

PMID:
11375946
12.

Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults.

Lindsay J, Punekar YS, Morris J, Chung-Faye G.

Aliment Pharmacol Ther. 2008 Jul;28(1):76-87. doi: 10.1111/j.1365-2036.2008.03709.x. Epub 2008 Apr 11.

13.

Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn's disease.

Doherty GA, Miksad RA, Cheifetz AS, Moss AC.

Inflamm Bowel Dis. 2012 Sep;18(9):1608-16. doi: 10.1002/ibd.21904. Epub 2011 Sep 8.

14.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

15.

Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.

Behm BW, Bickston SJ.

Cochrane Database Syst Rev. 2008 Jan 23;(1):CD006893. doi: 10.1002/14651858.CD006893. Review.

PMID:
18254120
16.

Economic implications of biological therapies for Crohn's disease: review of infliximab.

Bodger K.

Pharmacoeconomics. 2005;23(9):875-88. Review.

PMID:
16153132
17.

Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn's disease: a randomized multicenter trial (LIR!C-trial).

Eshuis EJ, Bemelman WA, van Bodegraven AA, Sprangers MA, Bossuyt PM, van Milligen de Wit AW, Crolla RM, Cahen DL, Oostenbrug LE, Sosef MN, Voorburg AM, Davids PH, van der Woude CJ, Lange J, Mallant RC, Boom MJ, Lieverse RJ, van der Zaag ES, Houben MH, Vecht J, Pierik RE, van Ditzhuijsen TJ, Prins HA, Marsman WA, Stockmann HB, Brink MA, Consten EC, van der Werf SD, Marinelli AW, Jansen JM, Gerhards MF, Bolwerk CJ, Stassen LP, Spanier BW, Bilgen EJ, van Berkel AM, Cense HA, van Heukelem HA, van de Laar A, Slot WB, Eijsbouts QA, van Ooteghem NA, van Wagensveld B, van den Brande JM, van Geloven AA, Bruin KF, Maring JK, Oldenburg B, van Hillegersberg R, de Jong DJ, Bleichrodt R, van der Peet DL, Dekkers PE, Goei TH, Stokkers PC.

BMC Surg. 2008 Aug 22;8:15. doi: 10.1186/1471-2482-8-15.

18.

Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn's Disease Patients Failing Infliximab.

Steenholdt C, Brynskov J, Thomsen OØ, Munck LK, Fallingborg J, Christensen LA, Pedersen G, Kjeldsen J, Jacobsen BA, Oxholm AS, Kjellberg J, Bendtzen K, Ainsworth MA.

Dig Dis Sci. 2015 Sep;60(9):2762-70. doi: 10.1007/s10620-015-3581-4. Epub 2015 Feb 12.

PMID:
25673037
19.

Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease.

Akobeng AK, Zachos M.

Cochrane Database Syst Rev. 2004;(1):CD003574. Review.

PMID:
14974022
20.

Natalizumab for induction of remission in Crohn's disease.

Macdonald JK, McDonald JW.

Cochrane Database Syst Rev. 2006 Jul 19;(3):CD006097. Review. Update in: Cochrane Database Syst Rev. 2007;(1):CD006097.

PMID:
16856112

Supplemental Content

Support Center